Literature DB >> 32622066

Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis.

Rebecca E H Whiting1, Jacqueline W Pearce2, Daniella P Vansteenkiste2, Katherine Bibi2, Stefanie Lim2, Grace Robinson Kick3, Leilani J Castaner1, John Sinclair4, Sundeep Chandra4, Annalisa Nguyen4, Charles A O'Neill4, Martin L Katz5.   

Abstract

CLN2 neuronal ceroid lipofuscinosis is a hereditary neurodegenerative disorder characterized by progressive vision loss, neurological decline, and seizures. CLN2 disease results from mutations in TPP1 that encodes the lysosomal enzyme tripeptidyl peptidase-1 (TPP1). Children with CLN2 neuronal ceroid lipofuscinosis experience ocular disease, characterized by progressive retinal degeneration associated with impaired retinal function and gradual vision loss culminating in total blindness. A similar progressive loss of retinal function is also observed in a dog CLN2 model with a TPP1 null mutation. A study was conducted to evaluate the efficacy of periodic intravitreal injections of recombinant human (rh) TPP1 in inhibiting retinal degeneration and preserving retinal function in the canine model. TPP1 null dogs received periodic intravitreal injections of rhTPP1 in one eye and vehicle in the other eye beginning at approximately 12 weeks of age. Ophthalmic exams, in vivo ocular imaging, and electroretinography (ERG) were repeated regularly to monitor retinal structure and function. Retinal histology was evaluated in eyes collected from these dogs when they were euthanized at end-stage neurological disease (43-46 weeks of age). Intravitreal rhTPP1 dosing prevented disease-related declines in ERG amplitudes in the TPP1-treated eyes. At end-stage neurologic disease, TPP1-treated eyes retained normal morphology while the contralateral vehicle-treated eyes exhibited loss of inner retinal neurons and photoreceptor disorganization typical of CLN2 disease. The treatment also prevented the development of disease-related focal retinal detachments observed in the control eyes. Uveitis occurred secondary to the administration of the rhTPP1 but did not hinder the therapeutic benefits. These findings demonstrate that periodic intravitreal injection of rhTPP1 preserves retinal structure and function in canine CLN2 disease.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Electroretinogram; Genetic diseases; Intravitreal drug delivery; Retina; Retinal degeneration; Uveitis

Mesh:

Substances:

Year:  2020        PMID: 32622066      PMCID: PMC7484259          DOI: 10.1016/j.exer.2020.108130

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  46 in total

1.  Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.

Authors:  Christopher J Tracy; Rebecca E H Whiting; Jacqueline W Pearce; Baye G Williamson; Daniella P Vansteenkiste; Lauren E Gillespie; Leilani J Castaner; Jeffrey N Bryan; Joan R Coates; Cheryl A Jensen; Martin L Katz
Journal:  Exp Eye Res       Date:  2016-09-13       Impact factor: 3.467

Review 2.  Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins.

Authors:  Krishna Radhakrishnan; Nirmal Sonali; Miguel Moreno; Jayabalan Nirmal; Alexandra A Fernandez; Subbu Venkatraman; Rupesh Agrawal
Journal:  Drug Discov Today       Date:  2016-11-03       Impact factor: 7.851

Review 3.  Noninfectious Inflammatory Response following Intravitreal Bevacizumab Injections: Description of a Cluster of Cases in Two Centers and a Review of the Literature.

Authors:  Omer Trivizki; Shulamit Schwartz; Neta Negri; Anat Loewenstein; Gilad Rabina; Shiri Shulman
Journal:  Ophthalmologica       Date:  2018-08-31       Impact factor: 3.250

4.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

Authors:  Magdalena G Krzystolik; Mehran A Afshari; Anthony P Adamis; Jacques Gaudreault; Evangelos S Gragoudas; Norman A Michaud; Wenjun Li; Edward Connolly; Charles A O'Neill; Joan W Miller
Journal:  Arch Ophthalmol       Date:  2002-03

5.  Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Michael Chang; Jonathan D Cooper; David E Sleat; Seng H Cheng; James C Dodge; Marco A Passini; Peter Lobel; Beverly L Davidson
Journal:  Mol Ther       Date:  2008-02-12       Impact factor: 11.454

Review 6.  Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy.

Authors:  C E Egwuagu; L Sun; S-H Kim; I M Dambuza
Journal:  Curr Mol Med       Date:  2015       Impact factor: 2.222

7.  Pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Rebecca E H Whiting; Kristina Narfström; Gang Yao; Jacqueline W Pearce; Joan R Coates; Leilani J Castaner; Martin L Katz
Journal:  Exp Eye Res       Date:  2013-10-14       Impact factor: 3.467

Review 8.  Sterile endophthalmitis after intravitreal injections.

Authors:  Joaquín Marticorena; Vito Romano; Francisco Gómez-Ulla
Journal:  Mediators Inflamm       Date:  2012-08-29       Impact factor: 4.711

Review 9.  Immune modulation by mesenchymal stem cells.

Authors:  Wei Jiang; Jianyong Xu
Journal:  Cell Prolif       Date:  2019-11-15       Impact factor: 6.831

10.  Retinal pathology in a canine model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Martin L Katz; Joan R Coates; Jocelyn J Cooper; Dennis P O'Brien; Manbok Jeong; Kristina Narfström
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-14       Impact factor: 4.925

View more
  5 in total

1.  Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.

Authors:  Rebecca E H Whiting; Grace Robinson Kick; Juri Ota-Kuroki; Stefanie Lim; Leilani J Castaner; Cheryl A Jensen; Joseph Kowal; Annalisa Nguyen; Carley Corado; Charles A O'Neill; Martin L Katz
Journal:  Exp Eye Res       Date:  2020-07-04       Impact factor: 3.770

2.  Ocular therapies for neuronal ceroid lipofuscinoses: more than meets the eye.

Authors:  Samantha J Murray; Nadia L Mitchell
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

Review 3.  Experimental Therapeutic Approaches for the Treatment of Retinal Pathology in Neuronal Ceroid Lipofuscinoses.

Authors:  Udo Bartsch; Stephan Storch
Journal:  Front Neurol       Date:  2022-04-18       Impact factor: 4.003

4.  Visual system pathology in a canine model of CLN5 neuronal ceroid lipofuscinosis.

Authors:  Grace Robinson Kick; Elizabeth J Meiman; Julianna C Sabol; Rebecca E H Whiting; Juri Ota-Kuroki; Leilani J Castaner; Cheryl A Jensen; Martin L Katz
Journal:  Exp Eye Res       Date:  2021-06-30       Impact factor: 3.770

5.  An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy.

Authors:  Dorothy A Thompson; Siân E Handley; Robert H Henderson; Oliver R Marmoy; Paul Gissen
Journal:  Eye (Lond)       Date:  2021-07-16       Impact factor: 3.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.